Identification and In Silico Analysis of Novel von Hippel-Lindau (VHL) Gene Variants from a Large Population

Annals of Human Genetics

Volumn 75, Issue 4, 2011, Pages 483-496

  Leonardi, Emanuela ^a   Martella, Maddalena ^a   Tosatto, Silvio C E ^a   Murgia, Alessandra ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiogenesis; Molecular genetics; Oncology; Structural bioinformatics; VHL

Indexed keywords

VON HIPPEL LINDAU PROTEIN;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; GENE; GENE DELETION; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VHL GENE; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADULT; CHILD; COMPUTERS; HUMANS; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; POPULATION SURVEILLANCE; PROTEIN FOLDING; SEQUENCE DELETION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79958845071     PISSN: 00034800     EISSN: 14691809     Source Type: Journal    
DOI: 10.1111/j.1469-1809.2011.00647.x     Document Type: Article

References (71)

1. Abbott, M. A., Nathanson, K. L., Nightingale, S., Maher, E. R. & Greenstein, R. M. (2006) The von Hippel-Lindau (VHL) germline mutation V84L manifests as early-onset bilateral pheochromocytoma. Am J Med Genet A 140, 685-690.
2. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D. J. (1997) Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 25, 3389-3402.
3. Bairoch, A., Apweiler, R., Wu, C. H., Barker, W. C., Boeckmann, B., Ferro, S., Gasteiger, E., Huang, H., Lopez, R., Magrane, M., Martin, M. J., Natale, D. A., O'donovan, C., Redaschi, N. & Yeh, L. S. (2005) The universal protein resource (UniProt). Nucleic Acids Res 33, D154-D159.
4. Beroud, C., Joly, D., Gallou, C., Staroz, F., Orfanelli, M. T. & Junien, C. (1998) Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res 26, 256-258.
5. Bourne, P. E., Addess, K. J., Bluhm, W. F., Chen, L., Deshpande, N., Feng, Z., Fleri, W., Green, R., Merino-Ott, J. C., Townsend-Merino, W., Weissig, H., Westbrook, J. & Berman, H. M. (2004) The distribution and query systems of the RCSB protein data bank. Nucleic Acids Res 32 Database issue, D223-D225.
6. Bromberg, Y. & Rost, B. (2007) SNAP: Predict effect of non-synonymous polymorphisms on function. Nucleic Acids Res 35, 3823-3835.
7. Capriotti, E., Fariselli, P., Rossi, I. & Casadio, R. (2008) A three-state prediction of single point mutations on protein stability changes. BMC bioinformatics 9 (Suppl 2), S6.
8. Casarin, A., Martella, M., Polli, R., Leonardi, E., Anesi, L. & Murgia, A. (2006) Molecular characterization of large deletions in the von Hippel-Lindau (VHL) gene by quantitative real-time PCR: The hypothesis of an alu-mediated mechanism underlying VHL gene rearrangements. Mol Diagn Ther 10, 243-249.
9. Chauveau, D., Burckle, C., Beroud, C., Correas, J. M., Duclos, J. M., Michel, P., Richard, S. & Grunfeld, J. P. (2002) Diagnosis of pheochromocytoma and laparoscopic adrenalectomy in two anephric patients with von Hippel-Lindau disease. Am J Kidney Dis 39, E6.
10. Clifford, S. C., Cockman, M. E., Smallwood, A. C., Mole, D. R., Woodward, E. R., Maxwell, P. H., Ratcliffe, P. J. & Maher, E. R. (2001) Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10, 1029-1038.
11. Corn, P. G., Mcdonald, E. R., 3rd, Herman, J. G. & El-Deiry, W. S. (2003) Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet 35, 229-237.
12. Crossey, P. A., Eng, C., Ginalska-Malinowska, M., Lennard, T. W., Wheeler, D. C., Ponder, B. A. & Maher, E. R. (1995) Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet 32, 885-886.
13. Crossey, P. A., Richards, F. M., Foster, K., Green, J. S., Prowse, A., Latif, F., Lerman, M. I., Zbar, B., Affara, N. A., Ferguson-Smith, M. A., Buys C. H. C. M. & Maher E. R. (1994) Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3, 1303-1308.
14. Ferrer-Costa, C., Gelpi, J. L., Zamakola, L., Parraga, I., De La Cruz, X. & Orozco, M. (2005) PMUT: A web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21, 3176-3178.
15. Forman, J. R., Worth, C. L., Bickerton, G. R., Eisen, T. G. & Blundell, T. L. (2009) Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis. Proteins 77, 84-96.
16. Franke, G., Bausch, B., Hoffmann, M. M., Cybulla, M., Wilhelm, C., Kohlhase, J., Scherer, G. & Neumann, H. P. (2009) Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients. Hum Mutat 30, 776-786.
17. Gallou, C., Longuemaux, S., Delomenie, C., Mejean, A., Martin, N., Martinet, S., Palais, G., Bouvier, R., Droz, D., Krishnamoorthy, R., Junien, C., Beroud, C. & Dupret, J. M. (2001) Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma. Pharmacogenetics 11, 521-535.
18. Gouet, P., Courcelle, E., Stuart, D. I. & Metoz, F. (1999) ESPript: Analysis of multiple sequence alignments in PostScript. Bioinformatics 15, 305-308.
19. Grosfeld, A., Stolze, I. P., Cockman, M. E., Pugh, C. W., Edelmann, M., Kessler, B., Bullock, A. N., Ratcliffe, P. J. & Masson, N. (2007) Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor. J Biol Chem 282, 13264-13269.
20. Guo, Y., Schoell, M. C. & Freeman, R. S. (2009) The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). Oncogene 28, 1864-1874.
21. Hebsgaard, S. M., Korning, P. G., Tolstrup, N., Engelbrecht, J., Rouze, P. & Brunak, S. (1996) Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res 24, 3439-3452.
22. Hergovich, A., Lisztwan, J., Thoma, C. R., Wirbelauer, C., Barry, R. E. & Krek, W. (2006) Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol Cell Biol 26, 5784-5796.
23. Hes, F. J., Van Der Luijt, R. B., Janssen, A. L., Zewald, R. A., De Jong, G. J., Lenders, J. W., Links, T. P., Luyten, G. P., Sijmons, R. H., Eussen, H. J., Halley, D. J., Lips, C. J., Pearson, P. L., Van Den Ouweland, A. M. & Majoor-Krakauer, D. F. (2007) Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, southern blot analysis and multiplex ligation-dependent probe amplification. Clin Genet 72, 122-129.
24. Hoffman, M. A., Ohh, M., Yang, H., Klco, J. M., Ivan, M. & Kaelin, W. G., Jr. (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10, 1019-1027.
25. Iturrioz, X., Durgan, J., Calleja, V., Larijani, B., Okuda, H., Whelan, R. & Parker, P. J. (2006) The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta. Biochem J 397, 109-120.
26. Kabsch, W. & Sander, C. (1983) Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637.
27. Kaelin, W. G. (2007) Von Hippel-Lindau disease. Ann Rev Pathol 2, 145-173.
28. Kaelin, W. G., Jr. (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8, 865-873.
29. Kaelin, W. G., Jr. & Maher, E. R. (1998) The VHL tumour-suppressor gene paradigm. Trends Genet 14, 423-426.
30. Kamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, R. C., Conaway, J. W. & Nakayama, K. I. (2004) VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 18, 3055-3065.
31. Khan, S. & Vihinen, M. (2010) Performance of protein stability predictors. Human mutation 31, 675-684.
32. Knauth, K., Bex, C., Jemth, P. & Buchberger, A. (2006) Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Oncogene 25, 370-377.
33. Knauth, K., Cartwright, E., Freund, S., Bycroft, M. & Buchberger, A. (2009) VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL. J Biol Chem 284, 10514-10522.
34. Kuzmin, I., Duh, F. M., Latif, F., Geil, L., Zbar, B. & Lerman, M. I. (1995) Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene 10, 2185-2194.
35. Kuznetsova, A. V., Meller, J., Schnell, P. O., Nash, J. A., Ignacak, M. L., Sanchez, Y., Conaway, J. W., Conaway, R. C. & Czyzyk-Krzeska, M. F. (2003) von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA 100, 2706-2711.
36. Landau, M., Mayrose, I., Rosenberg, Y., Glaser, F., Martz, E., Pupko, T. & Ben-Tal, N. (2005) ConSurf 2005: The projection of evolutionary conservation scores of residues on protein structures. Nucleic Acids Res 33, W299-W302.
37. Lee, C. M., Hickey, M. M., Sanford, C. A., Mcguire, C. G., Cowey, C. L., Simon, M. C. & Rathmell, W. K. (2009) VHL type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene 28, 1694-1705.
38. Lee, S., Nakamura, E., Yang, H., Wei, W., Linggi, M. S., Sajan, M. P., Farese, R. V., Freeman, R. S., Carter, B. D., Kaelin, W. G., Jr. & Schlisio, S. (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer cell 8, 155-167.
39. Leonardi, E., Murgia, A. & Tosatto, S. C. (2009) Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network. FEBS Lett 583, 3704-3710;
40. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M. & Krek, W. (1999) The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13, 1822-1833.
41. Liu, J. & Nussinov, R. (2008) Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. Proc Natl Acad Sci USA 105, 901-906.
42. Liu, J. & Nussinov, R. (2009) The mechanism of ubiquitination in the cullin-RING E3 ligase machinery: Conformational control of substrate orientation. PLoS Comput Biol, 5, e1000527.
43. Lolkema, M. P., Mans, D. A., Snijckers, C. M., Van Noort, M., Van Beest, M., Voest, E. E. & Giles, R. H. (2007) The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2. FEBS Lett 581, 4571-4576.
44. Lonser, R. R., Glenn, G. M., Walther, M., Chew, E. Y., Libutti, S. K., Linehan, W. M. & Oldfield, E. H. (2003) von Hippel-Lindau disease. Lancet 361, 2059-2067.
45. Martella, M., Salviati, L., Casarin, A., Trevisson, E., Opocher, G., Polli, R., Gross, D. & Murgia, A. (2006) Molecular analysis of two uncharacterized sequence variants of the VHL gene. J Hum Genet 51, 964-968.
46. Masso, M. & Vaisman, I. I. (2008) Accurate prediction of stability changes in protein mutants by combining machine learning with structure based computational mutagenesis. Bioinformatics, 24, 2002-2009.
47. Min, J. H., Yang, H., Ivan, M., Gertler, F., Kaelin, W. G., Jr. & Pavletich, N. P. (2002) Structure of an HIF-1alpha -pVHL complex: Hydroxyproline recognition in signaling. Science 296, 1886-1889.
48. Nagy, E. & Maquat, L. E. (1998) A rule for termination-codon position within intron-containing genes: When nonsense affects RNA abundance. Trends Biochem Sci 23, 198-199.
49. Nordstrom-O'Brien, M., Van Der Luijt, R. B., Van Rooijen, E., Van Den Ouweland, A. M., Majoor-Krakauer, D. F., Lolkema, M. P., Van Brussel, A., Voest, E. E. & Giles, R. H. (2010) Genetic analysis of von Hippel-Lindau disease. Hum Mutat 31, 521-537.
50. Ohh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M., Stemmer-Rachamimov, A. O., Louis, D. N., Gavin, B. J., Kley, N., Kaelin, W. G., Jr. & Iliopoulos, O. (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1, 959-968.
51. Ong, K. R., Woodward, E. R., Killick, P., Lim, C., Macdonald, F. & Maher, E. R. (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28, 143-149.
52. Pettigrew, C. A. & Brown, M. A. (2008) Pre-mRNA splicing aberrations and cancer. Front Biosci 13, 1090-1105.
53. Ramensky, V., Bork, P. & Sunyaev, S. (2002) Human non-synonymous SNPs: Server and survey. Nucleic Acids Res 30, 3894-3900.
54. Reese, M. G., Eeckman, F. H., Kulp, D. & Haussler, D. (1997) Improved splice site detection in Genie. J Comput Biol 4, 311-323.
55. Ritter, M. M., Frilling, A., Crossey, P. A., Hoppner, W., Maher, E. R., Mulligan, L., Ponder, B. A. & Engelhardt, D. (1996) Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab 81, 1035-1037.
56. Roe, J. S., Kim, H., Lee, S. M., Kim, S. T., Cho, E. J. & Youn, H. D. (2006) p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22, 395-405.
57. Roe, J. S. & Youn, H. D. (2006) The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle (Georgetown, TX) 5, 2054-2056.
58. Sommer, I., Toppo, S., Sander, O., Lengauer, T. & Tosatto, S. C. (2006) Improving the quality of protein structure models by selecting from alignment alternatives. BMC Bioinformatics 7, 364.
59. Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S., Abeysinghe, S., Krawczak, M. & Cooper, D. N. (2003) Human gene mutation database (HGMD): 2003 update. Hum Mutat 21, 577-581.
60. Sutovsky, H. & Gazit, E. (2004) The von Hippel-Lindau tumor suppressor protein is a molten globule under native conditions: Implications for its physiological activities. J Biol Chem 279, 17190-17196.
61. Tang, N., Mack, F., Haase, V. H., Simon, M. C. & Johnson, R. S. (2006) pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol 26, 2519-2530.
62. Thoma, C. R., Frew, I. J. & Krek, W. (2007) The VHL tumor suppressor: Riding tandem with GSK3beta in primary cilium maintenance. Cell Cycle (Georgetown, TX) 6, 1809-1813.
63. Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994) CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22, 4673-4680.
64. Thusberg, J. & Vihinen, M. (2009) Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat 30, 703-714.
65. Turturro, F. (2009) Beyond the Knudson's hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a "gene modifier." J Mol Med (Berlin, Germany) 87, 591-593.
66. Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E. & Berendsen, H. J. (2005) GROMACS: Fast, flexible, and free. J Comput Chem 26, 1701-1718.
67. Wagner, E. & Lykke-Andersen, J. (2002) mRNA surveillance: The perfect persist. J Cell Sci 115, 3033-3038.
68. Yin, S., Ding, F. & Dokholyan, N. V. (2007) Eris: An automated estimator of protein stability. Nat Methods 4, 466-467.
69. Yue, P., Melamud, E. & Moult, J. (2006) SNPs3D: Candidate gene and SNP selection for association studies. BMC Bioinformatics 7, 166.
70. Zhang, J. & Maquat, L. E. (1997) Evidence that translation reinitiation abrogates nonsense-mediated mRNA decay in mammalian cells. EMBO J 16, 826-833.
71. Zhou, M. I., Wang, H., Ross, J. J., Kuzmin, I., Xu, C. & Cohen, H. T. (2002) The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. J Biol Chem 277, 39887-39898.